AZD2281

DRUG13 trials

Conditions

Advanced Solid TumorsBreast CancerCancerMetastatic Breast CancerNeoplasm MetastasisOvarian CancerOvarian CarcinomaOvarian Neoplasms

Phase 1

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

CompletedNCT00633269

AstraZenecaNeoplasm Metastasis

Start: 2008-04-30End: 2008-10-31Target: 6Updated: 2009-01-14

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

CompletedNCT00707707

AstraZenecaBreast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer

Start: 2008-09-15End: 2018-02-19Updated: 2018-03-06

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

CompletedNCT00710268

AstraZenecaNeoplasm Metastasis

Start: 2008-06-30End: 2009-11-30Updated: 2015-01-14

Phase I Comparative Bioavailability Study

Active, not recruitingNCT00777582

AstraZenecaSolid Tumors

Start: 2008-10-27End: 2026-03-31Updated: 2026-01-13

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

CompletedNCT00782574

AstraZenecaAdvanced Solid Tumors

Start: 2008-11-12End: 2023-12-07Updated: 2023-12-21

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

TerminatedNCT00819221

AstraZenecaSolid Tumors

Start: 2009-01-05End: 2021-12-22Updated: 2022-08-30

A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours

CompletedCTIS2023-507904-30-00

AstraZeneca ABsolid tumors

Start: 2020-01-27End: 2025-02-04Target: 25Updated: 2025-05-26

Phase 2

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

CompletedNCT00628251

AstraZenecaOvarian Neoplasms

Start: 2008-07-30End: 2018-09-19Updated: 2019-12-05

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

CompletedNCT00679783

AstraZenecaBreast Cancer, Ovarian Carcinoma

Start: 2008-07-08End: 2022-07-20Updated: 2023-07-12

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

CompletedNCT00753545

AstraZenecaOvarian Cancer

Start: 2008-08-28End: 2023-10-12Updated: 2025-02-03

OLAParib COmbinations

TerminatedNCT02576444

Joseph Paul EderCancer

Start: 2015-11-30End: 2019-11-18Updated: 2022-12-28

Phase 3

Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Not yet recruitingEUCTR2018-004720-11-ES

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Stage IV lung cancer condition MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic S

Start: 2019-06-18Target: 792Updated: 2019-06-30

Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Active, not recruitingEUCTR2018-004720-11-AT

Merck Sharp & Dohme LLCStage IV lung cancer condition MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10079440 T

Start: 2019-06-05Target: 1005Updated: 2024-05-21

2024-12-185 citations

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

Journal of Clinical Oncology2021-05-206 citations

PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.

Journal of Clinical Oncology2021-02-203 citations

DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment

International Journal of Gynecological Cancer2020-09-0314 citations

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Journal of Clinical Oncology2020-05-20106 citations

Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.

Journal of Clinical Oncology2020-05-2012 citations

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.

Journal of Clinical Oncology2020-05-208 citations

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Journal of Clinical Oncology2020-02-19287 citations

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.

2020-02-197 citations

Abstract A080: Olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations – OLAPCO

Molecular Cancer Therapeutics2019-12-018 citations

33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial

2019-09-017 citations

Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Journal of Clinical Oncology2019-05-2026 citations

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.

2018-12-0134 citations

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

2018-10-24185 citations

OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)

Annals of Oncology2018-10-011 citations

Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.

Journal of Clinical Oncology2018-05-203 citations

Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Journal of Clinical Oncology2017-05-2024 citations

Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

Journal of Clinical Oncology2017-05-204 citations

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Oncotarget2017-05-0492 citations

Phase III SOLO-2 Data Demonstrates High Survival Benefit of Olaparib

Oncology Times2017-04-28

20 more papers not shown

AZD2281

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers